Acquired by Astellas Pharma Inc. in July 2023
ISEE - IVERIC bio, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
ISEE price evolution
ISEE
| (in millions $) | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $467.57 | $476.3 | $153.1 | $141.11 |
| Short term investments | $132.35 | $170.53 | $167.44 | $170.85 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $611.54 | $662.83 | $329.48 | $317.22 |
| Long term investments | ||||
| Property, plant & equipment | $1.86 | $2.13 | $2.31 | $2.53 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.86 | $4 | $2.31 | $2.53 |
| Total investments | $132.35 | $170.53 | $167.44 | $170.85 |
| Total assets | $613.41 | $666.82 | $331.79 | $319.76 |
| Current liabilities | ||||
| Accounts payable | $18.03 | $22.84 | $11.6 | $8.18 |
| Deferred revenue | ||||
| Short long term debt | $0.77 | $1.19 | $1.6 | $1.72 |
| Total current liabilities | $39.37 | $35.59 | $24.59 | $26.48 |
| Long term debt | $96.99 | $96.57 | $47.68 | $0.33 |
| Total noncurrent liabilities | $96.99 | $96.58 | $47.68 | $0.33 |
| Total debt | $97.76 | $97.77 | $49.28 | $2.06 |
| Total liabilities | $136.36 | $132.17 | $72.26 | $26.81 |
| Shareholders' equity | ||||
| Retained earnings | -$937.03 | -$864.81 | -$805.75 | -$763.39 |
| Other shareholder equity | -$0.1 | -$0.23 | -$0.4 | -$0.53 |
| Total shareholder equity | $477.05 | $534.66 | $259.53 | $292.95 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $476.3 | $261.45 | $66.37 | $125.7 |
| Short term investments | $170.53 | $120.3 | $143.67 | |
| Net receivables | $1.76 | $0.88 | ||
| Inventory | ||||
| Total current assets | $662.83 | $387.49 | $216.6 | $128.62 |
| Long term investments | ||||
| Property, plant & equipment | $2.13 | $1.87 | $0.15 | $0.67 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $4 | $1.87 | $0.15 | $1.56 |
| Total investments | $170.53 | $120.3 | $143.67 | |
| Total assets | $666.82 | $389.36 | $216.75 | $130.19 |
| Current liabilities | ||||
| Accounts payable | $22.84 | $12.86 | $12.79 | $5.63 |
| Deferred revenue | ||||
| Short long term debt | $1.19 | $0.95 | $0.05 | $0.49 |
| Total current liabilities | $35.59 | $28.21 | $25.13 | $12.98 |
| Long term debt | $96.57 | $0.62 | $0.06 | |
| Total noncurrent liabilities | $96.58 | $0.62 | $0.06 | |
| Total debt | $97.77 | $1.57 | $0.12 | $0.49 |
| Total liabilities | $132.17 | $28.83 | $25.19 | $12.98 |
| Shareholders' equity | ||||
| Retained earnings | -$864.81 | -$679.6 | -$565.07 | -$480.53 |
| Other shareholder equity | -$0.23 | -$0.09 | $0 | |
| Total shareholder equity | $534.66 | $360.53 | $191.56 | $117.2 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $42.08 | $35.84 | $24.97 | $33.65 |
| Selling, general & administrative | $31.76 | $27.13 | $17.55 | $16.11 |
| Total operating expenses | $73.84 | $62.97 | $42.51 | $49.75 |
| Operating income | -$73.84 | -$62.97 | -$42.51 | -$49.75 |
| Income from continuing operations | ||||
| EBIT | -$72.23 | -$59.06 | -$42.35 | -$49.26 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$72.23 | -$59.06 | -$42.35 | -$49.26 |
| Income (for common shares) | -$72.23 | -$59.06 | -$42.35 | -$49.26 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $117.01 | $85.07 | $62.78 | $39.64 |
| Selling, general & administrative | $72.89 | $29.69 | $25.95 | $21.63 |
| Total operating expenses | $189.91 | $114.76 | $88.74 | $61.27 |
| Operating income | -$189.91 | -$114.76 | -$88.74 | -$61.27 |
| Income from continuing operations | ||||
| EBIT | -$185.21 | -$114.52 | -$88.24 | -$58.97 |
| Income tax expense | -$3.69 | -$0.11 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | -$185.21 | -$114.52 | -$84.55 | -$58.86 |
| Income (for common shares) | -$185.21 | -$114.52 | -$84.55 | -$58.86 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Net income | -$72.23 | -$59.06 | -$42.35 | -$49.26 |
| Operating activities | ||||
| Depreciation | $0.07 | $0.06 | $0.04 | $0.02 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.9 | $8.35 | $6.56 | $6.39 |
| Total cash flows from operations | -$50.59 | -$49.23 | -$41.12 | -$35.91 |
| Investing activities | ||||
| Capital expenditures | -$0.23 | $0.2 | -$0.23 | -$0.1 |
| Investments | $39.51 | -$2.07 | $3.61 | -$17.55 |
| Total cash flows from investing | $39.27 | -$1.87 | $3.38 | -$17.65 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.59 | $325.68 | $2.24 | $2.8 |
| Net borrowings | $48.63 | $47.48 | ||
| Total cash flows from financing | $2.59 | $374.31 | $49.72 | $2.8 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$8.73 | $323.2 | $11.99 | -$50.75 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$185.21 | -$114.52 | -$84.55 | -$58.86 |
| Operating activities | ||||
| Depreciation | $0.14 | $0.04 | $0.14 | $0.16 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $26.68 | $11.24 | $8.32 | $9.18 |
| Total cash flows from operations | -$163.77 | -$98.56 | -$66.1 | -$48.49 |
| Investing activities | ||||
| Capital expenditures | -$0.24 | -$0.36 | $0.15 | |
| Investments | -$50.04 | $21.66 | -$143.81 | |
| Total cash flows from investing | -$50.28 | $21.3 | -$143.81 | $0.15 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $332.8 | $272.33 | $150.58 | $42.84 |
| Net borrowings | $96.1 | |||
| Total cash flows from financing | $428.9 | $272.33 | $150.58 | $42.84 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $214.86 | $195.07 | -$59.33 | -$5.5 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 137.25M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$222.72M |
| EBIT | -$222.90M |
| Net Income | -$222.90M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 3.48 |
| Cash/Share | 3.41 |
| EPS | -$1.62 |
|---|---|
| ROA | -46.16% |
| ROE | -57.00% |
| Debt/Equity | 0.25 |
|---|---|
| Net debt/EBITDA | 1.49 |
| Current ratio | 15.53 |
| Quick ratio | 15.53 |